About this trial
The aim of the SURVIBIO study is to characterize accurate biomarkers for acute mesenteric ischemia, in particular at early stages.
In the study, the development of biomarkers will be based on the analysis of human biological samples from patients and controls that will be conserved in a biological library. Samples will be analysed in the Laboratory for Vascular Translational Sciences (LVTS, Inserm U1148), in the Department of Biochemistry (Pr Puy, Dr Peoc'h), in Paris V university , in Imperial College of London (Pr Dumas), in Jacques Monod Institute and in Maastricht University Medical Center . The candidate markers will be determined according to an a priori method (form markers already described in the literature) and with no a priori strategy using -omics methods.
Eligibility criteria
Qualifiers
age> 18 years
Acute abdominal pain requiring an injected abdominal injected CT scan, at best at non-injected / early arterial / portal time
Admitted or attended in Beaujon and / or Bichat hospitals
Patient covered by a social security scheme
Disqualifiers
None
Trial design
Treatments tested in this trial
- blood sampling